https://www.selleckchem.com/pr....oducts/shp099-dihydr
the identification of genes central to the induction, development, progression, and outcome of β-thalassemia will be a key point for directing personalized therapy. After 48 months, unresolved macular edema secondary to central retinal vein occlusion (CRVO) is present in more than half of the patients treated with ranibizumab/bevacizumab. Switching therapy to aflibercept, a more recent vascular endothelial growth factor-A (VEGF-A) inhibitor, as well as VEGF-B and placental growth factor inhibitor, might improve the clinic
Like
Comment
Share
